Clinical Outcome Following Total Hip Arthroplasty With the SMF Stem

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

126 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-02-27

Study Completion Date

2020-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, consecutive series, multicenter clinical study of clinical outcomes following total hip arthroplasty with the SMF stem.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Avenir® Cemented Hip Stem - PMCF

NCT03396224

Primary Osteoarthritis Post-Traumatic Osteoarthritis of Hip Femoral Neck Fractures +4 more

ACTIVE_NOT_RECRUITING

Fitmore Hip Stem PMCF Study: A Multi-centre, Non-comparative, Prospective Post-market Clinical Follow-up Study.

NCT03411044

Osteoarthritis Avascular Necrosis Rheumatoid Arthritis +1 more

COMPLETED

An MRI Investigation of Soft Tissues in Total Hip Arthroplasty

NCT01750606

Tissue Reaction Elevated Blood Ion Levels

UNKNOWN

Avenir Complete Post-Market Clinical Follow-Up Study

NCT04731077

Osteoarthritis, Hip Avascular Necrosis of Hip Avascular Necrosis of the Femoral Head +1 more

ACTIVE_NOT_RECRUITING NA

A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement

NCT00872573

Rheumatoid Arthritis Osteoarthritis Post-traumatic Arthritis +6 more

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of this study are to evaluate the safety and efficacy of the study device. This study will document any device-related, surgical or post-operative complication and adverse radiographic observations. Improvement in pain, function, and health economic data will be compared with improvements documented with other joint systems. Outcome measures will be quantified through statistical analysis of study device , HOOS questionnaire, radiographic assessments, Harris Hip Score, and adverse event reports.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Joint Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SMF mini-stem hip replacement recipient

Received the device via total hip arthroplasty

Total hip arthroplasty

Intervention Type DEVICE

Total hip arthroplasty

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Total hip arthroplasty

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Total hip replacement

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient presents with non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, avascular necrosis, rheumatoid arthritis of or any of it's composite diagnosis.
* Patient is of legal age to consent, is skeletally mature and at least 18 years old.
* Patient is willing to consent to participate in the study by signing and dating an IRB-approved consent form.
* Patient is in stable health and is free of or treated and stabilized for cardiac, pulmonary, hematological or other conditions that would pose excessive operative risk.

Exclusion Criteria

* Patient has poor bone stock and would make the procedure unjustifiable: A) patients which are under medical care for osteoporosis (taking hormones, Calcitonin or biphosphates) or for other metabolic pathologies, which could influence the quality of the bone (for example hyperparathyroidism, hyperthyreoidismus and osteomalacie) will be excluded from the study. B) patients suffering from Morbus Paget (osteodystrophia deformans) will be excluded from the study.
* Patient has conditions that tend to place increased loads on implants such as weight, chargot joint, muscular deficiencies and activity level, which are incompatible with a satisfactory long-term result: A) patients with a BMI \> 40 will be excluded from the study B) patients participating in high-impact sports like baseball, basketball, football, handball, hockey, karate, racquet-ball, running, soccer, water skiing or similar impact sports will be excluded from the study.
* Patient is over the age of 75.
* Skeletal immaturity: patients must be at least 18 years at the time of the operation.
* Patient has an active, local infection that would lead to increased bone resorption.
* Mental or neurological conditions that tend to pre-empt the patient's ability or willingness to restrict activities.
* Known sensitivity to materials of the implant.
* Patient is pregnant or plans to be come pregnant during the course of the study.
* Patient is a prisoner.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No